Frontier Pharma: Hepatitis C Market Report 2016 - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations" drug pipelines to their offering.

Despite the entry of these new therapies, there is a subgroup of patients that do not respond to current treatments, or relapse. In addition, HCV resistance to DAAs may also be a cause for concern, as the development of selection pressure by the host immune system in combination with DAA therapy may lead to outgrowth of resistant viruses. As such, the rationale for investment in first-in-class innovation remains strong.

First-in-class products account for a relatively small proportion of the hepatitis C pipeline. However, in comparison with historical hepatitis C trends, which saw virtually no first-in-class products approved over a large period up until 2011, the presence of a modest number of these products is promising. The first-in-class targets identified show considerable diversity, and the high number of novel pathways targeted by first-in-class products provides evidence of enhanced divergence in hepatitis C first-in-class innovation in recent years.

The escalating hepatitis C public healthcare need has resulted in a competitive market landscape

- What is the pathophysiology of hepatitis C?

- What are the common co-morbidities and complications?

- How has the emergence of new drug classes in the past decade impacted the treatment algorithm?

- What are the most significant unmet needs within the market?

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.

- Visualize the composition of the hepatitis C market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.

- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to hepatitis C, all first-in-class targets in the hepatitis C pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Key Topics Covered:

1 Tables & Figures

2 Executive Summary

3 The Case for Innovation

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation

6 Signaling Network, Disease Causation and Innovation Alignment

7 First-in-Class Target Evaluation

8 Strategic Consolidations

9 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/3kp5xv/frontier_pharma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Infectious Diseases Drugs, Infectious Disease Testing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Infectious Diseases Drugs, Infectious Disease Testing